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 New program, “Closer to Home,” will allow pregnant 
women in buprenorphine treatment for opioid 
dependence to get treatment closer to home and 
deliver at Copley Hospital instead of being required to 
go to Burlington
 Requires local physicians to prescribe buprenorphine 
to pregnant women 
 In creating the program, prescribing physicians have 
to decide policies around non-opioid substance use 
2a: Closer to Home 
 Currently, with non-pregnant patients, the prescribing 
physicians in the practice  differ with regard to policies 
toward marijuana use
 50-85% of people dependent on opioids use marijuana 
 In a previous study, 94% of marijuana users in treatment for 
opioids continued to use marijuana during treatment
 The creation of an evidence-based policy for marijuana use 
during buprenorphine treatment, especially during 
pregnancy, would be beneficial
2b: Closer to Home 
 In the US in 2009, treatment of neonates exposed to opioids 
cost $70-112 million.
 Opioid dependence during pregnancy is associated with 
intrauterine growth restriction, intrauterine fetal demise and 
stillbirth, preterm labor, placental abruption and postpartum 
hemorrhage. 
 Buprenorphine treatment in pregnancy increased prenatal care, 
reduces criminal activity, decreases neonatal morbidity and 
mortality, and increases likelihood that mothers will maintain 
custody of their children after delivery 
 As highlighted in the popular press lately, Vermont is very much 
a part of the opioid dependence epidemic 
3a: Public Health Cost
 Buprenorphine treatment, in comparison to 
methadone treatment, results in less severe neonatal 
abstinence syndrome and a shorter hospital stay, 
making the provision of buprenorphine to pregnant 
women who are opioid dependent an important 
public health matter. 
3b: Public Health Cost
 Based on discussions with providers, support staff, and 
attendance at an OB-Peds meeting focused on the 
implementation of this new program
 Opinions on marijuana use differed among members of the 
Closer to Home team, including buprenorphine prescribing 
physicians and nurses with specialized training: 
 “Marijuana is illegal and I don’t see how ignoring a patient 
obtaining drugs illegally is consistent with supporting 
recovery”
 Others felt that allowing marijuana use fit within their model 
for prescribing buprenorphine – they frequently described 
their role as “harm reduction”
4a: Community Perspective: Closer to 
Home team  
 Experts at the Substance Abuse Treatment Center at the 
University of Vermont shared their practice of encouraging 
abstinence from all illegal substances, and providing 
abstinence support if marijuana is identified as an issue for 
an individual, but not penalizing for marijuana use 
 They shared that the scientific literature has not found that 
marijuana use during medication assisted treatment for 
opioid dependence is associated with treatment outcome
4b: Community Perspective: 
Substance Abuse Treatment Experts
5: Intervention and Methodology
 The intervention is providing the 
developing “Closer to Home” 
program with education about 
marijuana use in opioid dependent 
pregnant women in order to make 
policies on this issue.
 The Closer to Home Treatment 
Coordinator and one of the 
prescribing physicians in the 
program were provided with a 
literature review, a bibliography 
on relevant sources, and copies of 
eight scientific papers on the 
topic. They plan on further 
distributing these materials.
 The evidence is in two forms
 Scientific literature review 
looking at:
 marijuana use and 
treatment outcomes in 
medication assisted opioid 
treatment (buprenorphine 
and methadone)
 Maternal and fetal effects of 
marijuana use in pregnancy
 Expert opinions and standard 
of care at other established 
substance abuse treatment 
programs for pregnant women
6a: Results of Literature Review
Marijuana Use During Opioid 
Replacement Therapy: 
 In a study of cannabis use among 
opioid-dependent youth in 
buprenorphine treatment found 
neither past marijuana use or use 
during treatment was associated 
with level of opioid use
 A study done at UVM found that 
66% of patients in a buprenorphine 
treatment program used 
marijuana and 94% of those 
continued to use marijuana during 
treatment despite encouragement 
to abstain. There was no 
relationship between marijuana 
use and treatment outcome
Fetal effects:
 inconclusive evidence and 
insufficient research
 Little evidence of intrauterine 
growth restriction, prematurity 
or low birth weight
 Some evidence of impaired 
neurodevelopmental 
outcomes in school-age 
children
 The Chittenden Clinic, a buprenorphine and methadone treatment center, 
does not penalize for marijuana use during medication assisted treatment. 
They do for illicit opioid, cocaine, alcohol and benzodiazepine use because 
these drugs are associated with poor treatment outcomes in the scientific 
literature
 The Comprehensive Obstetric and Gynecological Service (COGS) clinic at 
Fletcher Allen Health Care, that prescribes buprenorphine to pregnant 
women, does not consider marijuana use as treatment non-compliance 
 Overall, the program directors felt that the risks of withholding medication 
assisted opioid treatment to a pregnant woman far outweighed the risks of 
providing the treatment to a woman who uses marijuana. The risks sighted 
for continued illicit opioid use were overdose, death, and the negative fetal 
outcomes presented previously.
 The above is based on discussions with Name Withheld, Ph.D., Name 
Withheld, Ph.D. (both in the Departments of Psychiatry and Psychology at 
the University of Vermont) and Name Withheld, MD (in the Department of 
Obstetrics, Gynecology and Reproductive Services at the University of 
Vermont) 
6b: Standard of Care
 The best way to evaluate the effectiveness of this project would 
be to resurvey the prescribers and others involved in the Closer 
to Home program on their policies toward marijuana use in their 
buprenorphine patients, especially pregnant patients.
 Another possible outcome to evaluate would be if the program 
itself makes a standard policy, rather than allowing for personal 
preference 
 Limitations: A significant limitation of this study is that the 
dissemination of the literature review and standard of care 
findings will be determined by provider interest in reviewing the 
materials provided.  It would have also been useful to have some 
baseline statistics on marijuana use in the specific treatment 
population
7: Evaluation of effectiveness and 
limitations
 A workshop or lecture for prescribers and other 
practitioners in the Closer to Home program based on 
the findings of this study could increase knowledge 
and potentially change practices
 Additionally, discussions with patients around 
marijuana use and establishment of evidence based 
treatment for marijuana use could be a fruitful future 
project 
8: Recommendations for the future
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